Creatinine Clearance Cockcroft Gault Calculator

Creatinine is produced from muscle creatine phosphate at a rate roughly proportional to lean mass and cleared mainly by glomerular filtration, so at steady state the serum concentration is inversely related to filtration capacity. The Cockcroft-Gault equation exploits that relationship without a urine collection: the (140 minus age) term stands in for the age-related fall in nephron function of roughly 1 mL/min per year after the fourth decade, weight in kilograms serves as a proxy for muscle mass and therefore creatinine generation, and the constant 72 reconciles units. The 0.85 multiplier for women reflects an average 15 percent lower muscle mass. The output is creatinine clearance, not glomerular filtration rate; because roughly 10 to 20 percent of urinary creatinine arrives by tubular secretion rather than filtration, the estimate systematically runs above true GFR. Regulatory dosing categories are defined on this scale: 90 mL/min and above normal, 60 to 89 mild impairment, 30 to 59 moderate, 15 to 29 severe, and below 15 end-stage. Weight choice matters because adipose tissue generates little creatinine; using total body weight in obesity inflates the result, so adjusted body weight, ideal weight from the Devine formula plus 0.4 of the excess, is used once actual weight exceeds ideal by more than 20 percent. The equation misleads whenever creatinine generation is abnormal: amputees, patients with cirrhosis or sarcopenia, and the frail elderly can carry a normal serum creatinine on badly reduced filtration. Trimethoprim and cimetidine block tubular secretion and raise creatinine without changing GFR, and no steady-state equation is valid during acute kidney injury.

Donald Cockcroft and Henry Gault published the equation in Nephron in 1976, working from data on hospitalised patients at the Queen Mary Veterans Hospital in Montreal. Their derivation set was overwhelmingly male, and the 0.85 correction for women was an estimate applied by analogy from known sex differences in creatinine excretion rather than a coefficient fitted to female data. The purpose was practical: to spare patients the 24-hour urine collections then required for clearance measurement, which were burdensome and frequently mis-timed. Its durability owes less to accuracy than to timing. Through the 1980s and 1990s pharmaceutical companies conducted renal impairment pharmacokinetic studies using Cockcroft-Gault to stratify participants, and the resulting dose adjustments were written into approved product labelling on that scale, a practice reinforced by United States Food and Drug Administration guidance on studying drugs in renal impairment. Newer equations followed, the Modification of Diet in Renal Disease study equation from Andrew Levey and colleagues in 1999 and the CKD-EPI equation in 2009, refitted in 2021 to remove the race coefficient, and these are now preferred for diagnosing and staging chronic kidney disease. Because they estimate body-surface-indexed GFR rather than clearance, they are not interchangeable with the older equation for drug dosing, so clinical pharmacy has continued to calculate both. Assay standardisation to isotope dilution mass spectrometry, which lowered reported creatinine values, added a further complication to the interpretation of a formula calibrated on 1970s methods.